#pediatric obesity

Tirzepatide Cuts BMI Sharply in Adolescents With Obesity, Phase III Trial Finds

Tirzepatide Cuts BMI Sharply in Adolescents With Obesity, Phase III Trial Finds

Tirzepatide (Zepbound) produced substantial reductions in body mass index among adolescents with obesity in the phase III SURMOUNT-ADOLESCENTS trial. At week 72, participants on the once-weekly GLP-1/GIP drug alongside a healthy lifestyle program saw an 18.5% mean BMI reduction, while those on placebo saw a 0.5% increase. The trial met its primary endpoint, and all 10 key secondary outcomes also favored tirzepatide. Results were presented at the ObesityWeek annual meeting and published in JAMA. The researchers cautioned against escalating doses to the maximum tolerated level in routine care.

Hundreds of English Children Prescribed Weight-Loss Jabs, Figures Show

Hundreds of English Children Prescribed Weight-Loss Jabs, Figures Show

Hundreds of children in England are receiving prescriptions for GLP-1 medications, including some under 12, according to a Guardian investigation of NHS prescribing data. In the 2025-26 financial year, 419 prescriptions were issued to under-18s, 10 of them to children under 12. Experts say the figures likely understate the true total, and they stress that children who start these drugs need specialist supervision and long-term monitoring. The findings come as childhood obesity rates continue to rise and as new global guidance advises against giving obesity medications to children under 10.